We are live on ! Find out more
KCM

Knoll Capital Management Portfolio holdings

AUM $180M
1-Year Est. Return 66.11%
This Fund
S&P 500
This Quarter Est. Return
+1.9%
1 Year Est. Return
+66.11%
3 Year Est. Return
+268.55%
5 Year Est. Return
+741%
10 Year Est. Return
+10,877.35%
AUM
$254M
AUM Growth
-$2.96M
Cap. Flow
+$3.81M
Cap. Flow %
1.5%
Top 10 Hldgs %
99.59%
Holding
16
New
1
Increased
3
Reduced
2
Closed
1

Top Buys

Rank Stock Value
1
TOVX icon
Theriva Biologics
TOVX
+$3.14M
2
ARCT icon
Arcturus Therapeutics
ARCT
+$810K
3
ASPX
AUSPEX PHARMACEUTICALS INC COM STK (DE)
ASPX
+$587K
4
AMPE
Ampio Pharmaceuticals Inc.
AMPE
+$62K

Top Sells

Rank Stock Value
1
NWBO
Northwest Biotherapeutics, Inc. Common stock
NWBO
+$337K
2
NRX
NEPHROGENEX INC COM
NRX
+$217K
3
INO icon
Inovio Pharmaceuticals
INO
+$204K
4
CLRB icon
Cellectar Biosciences
CLRB
+$33K

Sector Composition

Rank Sector Weight
1 Healthcare 12.13%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MDVN
1
DELISTED
MEDIVATION, INC.
MDVN
$222M 87.2%
4,489,038
– –
AMPE
2
DELISTED
Ampio Pharmaceuticals Inc.
AMPE
$11.6M 4.57%
11,294
+58
+0.5% +$62K
TOVX icon
3
Theriva Biologics
TOVX
$10.2M
$4.96M 1.95%
389
+234
+151% +$3.14M
ARCT icon
4
Arcturus Therapeutics
ARCT
$157M
$3.23M 1.27%
123,616
+25,473
+26% +$810K
LUMO
5
DELISTED
Lumos Pharma, Inc. Common Stock
LUMO
$3.08M 1.21%
8,604
– –
KERX
6
DELISTED
Keryx Biopharmaceuticals Inc
KERX
$2.83M 1.11%
200,000
– –
ENLV icon
7
Enlivex Ltd
ENLV
$70.7M
$2.16M 0.85%
564
– –
ADXS
8
DELISTED
Advaxis Inc
ADXS
$1.8M 0.71%
15,000
– –
ASPX
9
DELISTED
AUSPEX PHARMACEUTICALS INC COM STK (DE)
ASPX
$1.05M 0.41%
+20,000
New +$587K
INO icon
10
Inovio Pharmaceuticals
INO
$79.8M
$754K 0.3%
6,841
-1,666
-20% -$204K
ADXSW
11
DELISTED
Advaxis Inc Warrants
ADXSW
$467K 0.18%
112,500
– –
GLMD icon
12
Galmed Pharmaceuticals
GLMD
$3.94M
$377K 0.15%
361
– –
PVCT
13
DELISTED
PROVECTUS BIOPHARMACEUTICALS, INC. (DE)
PVCT
$160K 0.06%
200,000
– –
NRX
14
DELISTED
NEPHROGENEX INC COM
NRX
$41K 0.02%
3,072
-46,928
-94% -$217K
CLRB icon
15
Cellectar Biosciences
CLRB
$19.3M
– –
0
– -$33K
NWBO
16
DELISTED
Northwest Biotherapeutics, Inc. Common stock
NWBO
– –
-67,035
Closed -$337K

Similar funds

MGWA
Monument Group Wealth Advisors Concord, Massachusetts $180M AUM 19.81% 1-Year Est. Return
AW
Alchemi Wealth Essex, Connecticut $180M AUM
FBC
Fairfield, Bush & Co Darien, Connecticut $180M AUM 39.51% 1-Year Est. Return
AIC
Aurora Investment Counsel Atlanta, Georgia $180M AUM 0.3% 1-Year Est. Return
AG
Amiral Gestion Paris, France $180M AUM 9.43% 1-Year Est. Return
PCA
Prospect Capital Advisors Sausalito, California $180M AUM 60.99% 1-Year Est. Return
HIC
Hamrick Investment Counsel Seattle, Washington $180M AUM
FFA
Frazier Financial Advisors Columbus, Ohio $181M AUM 11.16% 1-Year Est. Return

Knoll Capital Management's Q4 2014 Portfolio in Review

As of Q4 2014, Knoll Capital Management held 16 positions worth $254M, down 1.1% from $257M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Knoll Capital Management's Q4 2014 filing shows 1 new, 3 increased, 2 reduced and 1 closed positions. Its largest new stake was AUSPEX PHARMACEUTICALS INC COM STK (DE): 20,000 shares worth $1.05M. The largest sale was Northwest Biotherapeutics, Inc. Common stock, an estimated $337K.

By sector, the portfolio is most concentrated in Healthcare at 12% of assets, down from 13% a quarter earlier.

  • Knoll Capital Management's largest Q4 2014 buy was AUSPEX PHARMACEUTICALS INC COM STK (DE): 20,000 shares worth $1.05M.
  • Knoll Capital Management added most to Theriva Biologics in Q4 2014, an estimated $3.14M increase.
  • Knoll Capital Management's biggest Q4 2014 reduction was NEPHROGENEX INC COM, cutting an estimated $217K.
  • Knoll Capital Management fully exited Northwest Biotherapeutics, Inc. Common stock in Q4 2014, selling an estimated $337K.
  • Knoll Capital Management's ten largest holdings make up 100% of its $254M portfolio in Q4 2014.
  • Knoll Capital Management opened 1 new position and closed 1 in Q4 2014.
  • Knoll Capital Management's portfolio value fell 1.1% quarter-over-quarter to $254M.

Based on Knoll Capital Management's 13F filing for Q4 2014, filed 17 Feb 2015.